The abstract is read at the publisher; the summary is JClub's.
In the SANO trial for locally advanced oesophageal cancer patients with complete clinical response after neoadjuvant chemoradiotherapy, five-year overall survival was similar: 50% vs 54%.
- Why it matters: The key question is whether avoiding oesophagectomy in complete clinical responders maintains long-term survival while balancing tradeoffs in recurrence patterns and quality of life.
- What they did: In a multicentre stepped-wedge cluster-randomised non-inferiority design (2017–2021), 309 patients received active surveillance or standard surgery; five-year overall and disease-free survival were compared with Cox regression.
- The result: Five-year disease-free survival was not significantly different (HR 1.39, 95% CI 0.94–2.06), but distant metastases were higher with active surveillance (46% vs 29%, P<.01), and 43% avoided oesophagectomy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.